12/13
02:06 am
canf
Can-Fite BioPharma Ltd. (NYSE: CANF) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Can-Fite BioPharma Ltd. (NYSE: CANF) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
12/5
11:05 pm
canf
Can-Fite BioPharma Ltd. (NYSE: CANF) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
High
Report
Can-Fite BioPharma Ltd. (NYSE: CANF) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
12/5
08:01 am
canf
Can-Fite BioPharma Ltd. (NYSE: CANF) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Low
Report
Can-Fite BioPharma Ltd. (NYSE: CANF) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
12/4
07:15 am
canf
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite's Namodenoson Drug [Yahoo! Finance]
High
Report
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite's Namodenoson Drug [Yahoo! Finance]
12/4
07:00 am
canf
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
High
Report
8 Years Survival with Complete Cure for a Patient with Advanced Liver Cancer Being Treated with Can-Fite’s Namodenoson Drug
11/20
03:11 am
canf
Can-Fite BioPharma Ltd. (NYSE: CANF) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Can-Fite BioPharma Ltd. (NYSE: CANF) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/12
08:33 am
canf
Can-Fite BioPharma Ltd. (NYSE: CANF) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Low
Report
Can-Fite BioPharma Ltd. (NYSE: CANF) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
11/11
07:00 am
canf
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
Medium
Report
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
11/4
07:13 am
canf
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia [Yahoo! Finance]
Medium
Report
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia [Yahoo! Finance]
11/4
07:08 am
canf
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
High
Report
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
10/30
02:07 am
canf
Can-Fite BioPharma Ltd. (NYSE: CANF) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Can-Fite BioPharma Ltd. (NYSE: CANF) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
10/22
02:02 am
canf
Can-Fite BioPharma Ltd. (NYSE: CANF) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Can-Fite BioPharma Ltd. (NYSE: CANF) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
10/18
09:06 am
canf
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
Low
Report
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
10/14
11:07 pm
canf
Can-Fite BioPharma Ltd. (NYSE: CANF) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
High
Report
Can-Fite BioPharma Ltd. (NYSE: CANF) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
10/9
07:00 am
canf
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
Medium
Report
FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic Cancer
10/7
07:00 am
canf
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
Low
Report
Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29
9/24
07:00 am
canf
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis
Medium
Report
Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary Osteoarthritis